Paediatric Renal Disease

Similar documents
Childhood nephrotic syndrome practice guidelines

Management of Nephrotic Syndrome

Guidelines for the management of Nephrotic syndrome in children

This guideline describes the assessment and management of children and young people with nephrotic syndrome Key Words

Nephrotic Syndrome NS

Acute Kidney Injury (AKI) Undergraduate nurse education

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Clinical trials in childhood steroid sensitive nephrotic syndrome: the PREDNOS studies

Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.

Nephrotic Syndrome. Sara Alsharhan PharmD candidate, KSU 2014

CKD IN THE CLINIC. Session Content. Recommendations for commonly used medications in CKD. CKD screening and referral

Paediatrics Dr. Bakr Lecture 3 Nephrotic Syndrome

Acute Renal Failure. Dr Kawa Ahmad

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer

Southern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care

Nephrotic syndrome in children. Bashir Admani KPA Nephrology Precongress 24/4/2018

Nephrology. 3 rd Year Revision Session 06/05/17 Cathal Hannan

Doncaster & Bassetlaw. AKI guidelines for primary care

QUICK REFERENCE FOR HEALTHCARE PROVIDERS

Bulletin Independent prescribing information for NHS Wales

Renal Transporters- pathophysiology of drug - induced renal disorders. Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November

Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus

Shared Care Guideline Metolazone for fluid management in CKD (Adults)

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:

Mycophenolate Mofetil (MMF)

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

CKD & HT. Anne-Marie Angus

Acute Kidney Injury in The Acute Oncology Patient

WEEK. MPharm Programme. Acute Kidney Injury. Alan M. Green MPHM13: Acute Kidney Injury. Slide 1 of 47

Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree

A patient guide to membranous nephropathy

A guide to the treatment and management of Childhood Nephrotic Syndrome

Tacrolimus (Adoport, Prograf, Modigraf or Advagraf )

Family Medicine Counseling (Additional topics)

Burkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS

Introduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team

Stages of Chronic Kidney Disease (CKD)

Managing a child with nephrotic syndrome

Elevated Serum Creatinine, a simplified approach

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

Acute Kidney Injury shared guidance

Metabolic Syndrome and Chronic Kidney Disease

CHRONIC KIDNEY DISEASE DIAGNOSIS

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer

Dept of Diabetes Main Desk

P-RMS: FR/H/PSUR/0056/001

BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine

The evidence base for interventions to slow the progression of chronic kidney disease: Medical interventions. Jonathan Evans Paediatric Nephrologist

THE KIDNEY AND SLE LUPUS NEPHRITIS

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04

Additional file 2: Details of cohort studies and randomised trials

Over- and underfill: not all nephrotic states are equal. Detlef Bockenhauer

Professor Suetonia Palmer

ACUTE KIDNEY INJURY FOCUS ON OBSTETRICS DONNA HIGGINS, CLINICAL NURSE EDUCATOR, NORTHERN LINCOLNSHIRE HOSPITALS NHS FOUNDATION TRUST

Medicine Dr. Dana Lecture 1 Acute Kidney Injury (AKI)

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma

Minimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:

ECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic

Axitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.

Trust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)

Types Pathophysiology Clinical manifestations D.Dx. Investigations. Treatment. Complications.

CKD and risk management : NICE guideline

ALL MAINTENANCE (25-60 years)

Summary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup

Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012.

Learning Objectives. How big is the problem? ACUTE KIDNEY INJURY

Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day

Special Challenges and Co-Morbidities

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

M0BCore Safety Profile

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

ALL Phase 2 Induction (25-60 years)

Gemcitabine + Cisplatin Regimen

Chronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham

PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)

STANDARD treatment algorithm mmHg

Factsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction

Nephrotic syndrome Dr.Basma Adel FIFTH GRADE

Nice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care

Bevacizumab + Paclitaxel + Cisplatin

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy

Carboplatin, Paclitaxel and Bevacizumab (gynae)

Management of early chronic kidney disease

BC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

Essential Shared Care Agreement: Lithium

TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour

Please complete all sections 1. Name of Drug, Brand Name, Form and Strength

Dr.Nahid Osman Ahmed 1

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011

Acute Kidney Injury (AKI)

Byvalson. (nebivolol, valsartan) New Product Slideshow

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome

Gemcitabine, Carboplatin and Bevacizumab (gynae)

Transcription:

Pharmacy Department Paediatric Renal Disease Andrew.wignell@nuh.nhs.uk NUH Pharmacy

At the end of the session you should be able to: Determine the level/type of renal dysfunction in a child and what the implications might be for drug dosing. Identify common drug causes of Acute Kidney Injury and ways in which damage can be minimised or avoided. Describe the key features of Nephrotic Syndrome and outline the management of this condition.

Quiz NUH Pharmacy

What is normal?

Renal Dose Adjustments Calculate egfr using the Schwartz equation Child over 1 year: Estimated GFR (ml/min/1.73 m 2 )= 40 height (cm) serum creatinine (micromol/l) Neonate: Estimated GFR (ml/min/1.73 m 2 )= 30 height (cm) serum creatinine (micromol/l)

(Unless you are in Nottingham.)

Paediatric Renal Dosing BNFC Renal Drug Handbook Others.?

BNFC Cefuroxime Gentamicin

Others Drug Prescribing in Renal Failure, 5th Edition- Aronoff Micromedex Lexicomp / Up to Date

Renal Drug Handbook/Database Cefuroxime: Gentamicin:

Acute Kidney Injury

Case 1

Grading of AKI

Causes of AKI Pre-renal Sepsis Dehydration Shock Medication Post-renal Medication Obstruction Intra-renal Endotoxin Immune mediated Medication

Drug-Induced Pre-renal AKI Hypovolaemia: Excessive renal fluid loss: inappropriate use of diuretics. Systemic Hypotension: Usually due to cardiogenic shock/sepsis, but can arise due to pharmacological vasodilatation Renal Hypoperfusion: Afferent Arteriolar Constriction: NSAIDs, amphotericin, ciclosporin, adrenaline, noradrenaline Efferent Arteriolar Dilatation: ACE Inhibitors (ACEIs), Angiotensin II Inhibitors (ARBs)

ACEIs, ARBs and the Kidney Contraindicated in bilateral renal artery stenosis. Creatinine usually rises on starting/dose increase: NICE CCF Guideline: If egfr change is >25% or plasma creatinine >30% AND no other causes of deterioration is found stop ACEI/ARB or reduce dose to previously tolerated dose. Reno-protective in diabetic and non-diabetic microalbuminuria / proteinuria, irrespective of whether BP raised or not

Drug-induced Intra-renal AKI Drug Statins Contrast Media Aminoglycosides Effect on kidney Induce rhabdomyolysis Renal vasoconstriction & free radical production Direct toxic effect on tubular cells

Drug-Induced Post-Renal AKI Drug causes rare- due to obstruction of urine flow: Retroperitoneal haemorrhage due to overanticoagulation: bleeding creates external pressure on the ureters Retroperitoneal fibrosis: methotrexate, beta-blockers Crystallisation of urate and stone formation within the ureter: Tumour lysis syndrome Other drugs include: aciclovir, acetazolamide, cisplatin and naftidofuryl, topiramate, mirtazepine, risedronate

Medication Review in AKI Avoid and/or stop known nephrotoxins- where possible Avoid drugs which raise serum potassium. Stop/review antihypertensives (including diuretics). Adjust doses of drugs which are to continue in light of reduced renal clearance. Start with low doses and titrate slowly. Consider if alternative drug may be more suitable. Monitor levels whenever you can.

Not all cases are quite so obvious 9 year old girl Abdominal pain, joint pain and fever-? Cause Treated with cefuroxime No improvement Day 3: Trough level 5mg/L Dose increased by 20% Day 5: Trough level 8mg/L Serum creatinine 60 micromol/l Increased to 6-hourly Vancomycin added 15mg/kg 8-hourly Day 8: Trough level 25mg/L Serum creatinine 135 micromol/l

Not all cases are quite so obvious What are the possible learning points from this case? What information is missing? NUH Pharmacy

Not all cases are quite so obvious Learning points: Rapid increase in dose and frequency. Initial creatinine 25 micromol/l- increase not identified Concomitant use of NSAID not identified, Poor communication of plan to stop vanc

Prevention Avoid Nephrotoxic preparations / combinations. If unavoidable, monitor patients very closely. Remember that 25-50% of kidney function may have been lost before any rise in creatinine seen. Sick day rules for patients on ACE Inhibitors / ARBs. Be alert to the risk factors.

Sick Day Rules for ACE Inhibitors/ARBs NUH Pharmacy

Risk Factors for AKI Pre-renal: Limited access to fluids. Hypovolaemia and / or hypotension Sepsis Deteriorating PEWS Others: Heart Failure Liver Disease Haematological maligancy Nephrotoxic drugs Intra-renal: Chronic Kidney Disease History of AKI or oliguria Severe diarrhoea, particularly bloody diarrhoea. Signs or symptoms of nephritis Urinary obstruction. Renal Transplant

Nephrotic Sydrome

What is it?

What is it? Characterised by: Heavy proteinuria (protein:creatinine ratio > 250mg/mmol). Hypoalbuminaemia (serum albumin <25g/l). Oedema. Relapsing/Remitting Condition. Annual incidence in the UK of 2 per 100,000 children. More common in children from South Asia with an incidence up to 16 per 100 000 children.

Initial Treatment Aim is to induce remission with steroids and therefore promote diuresis. Most patients respond within 7-14 days. Prednisolone 60mg/m 2 (max 80mg) once daily for 28 days, then 40 mg/m 2 on alternate days for the next 28 days and then stop. Intensified Regimen: Weeks 1-4: 60 mg/m 2 /day Weeks 5 8: 40 mg/m 2 on alternate days Weeks 9 12: 25 mg/m 2 on alternate days Weeks 13-17 10 mg/m 2 then stop. PREDNOS Study Children who do not respond to prednisolone within 28 days need a renal biopsy.

Preventing Complications Hypovolaemia Increases the risk of thrombosis. Tachycardia, hypertension, cool peripheries and delayed capillary refill time. If severe consider albumin and thromboprophylaxis. Give albumin if symptomatic hypovolaemia or severe diuretic resistant oedema. Shock: 4.5% albumin 20 ml/kg over 30-60 mins repeated if necessary. Mild hypovolaemia + oedema = 20% albumin 5 ml/kg (1g/kg) over 4 hrs. Preventing Thrombosis: Avoid hypovolaemia Prevent sepsis Encourage mobilisation and avoid bedrest Consider TEDS and LMWH.

Preventing Complications Oedema and Ascites: Fluid restriction and low salt diet. Diuretics if severe/worsening oedema/ascites in the absence of hypovolaemia. Usually furosemide and spironolactone. Can add metolazone. Infection: Oral Penicillin V given to oedematous/ascitic patients to protect against pneumococcal infection. 125 mg twice daily if 0-5yrs 250 mg twice daily 5-12 yrs 500mg twice daily if > 12 years. Give Pneumovax II pneumococcal vaccine if not already given.

Classification Steroid Sensitive (SSNS). Steroid Resistant (SRNS). Frequently Replapsing (FRNS). Steroid Dependant (SDNS).

Steroid Sensitive NS Most cases will respond completely to steroids. Some will fail to come off steroids completely. 80% will have a relapse: May be frequent

Relapses Often triggered by viral infection. Treated with high dose steroids to induce remission. May be possible to prevent relapses by giving a low dose of daily steroids for 5 days at the time of an URTI without waiting for proteinuria to develop. Potential to have a large impact on long-term steroid burden. Subject of a national multicentre trial, PREDNOS2.

Steroid Dependant / Frequently Relapsing NS

Levamisole Increased likelihood of remission when given for 16 weeks May be best suited in frequent relapsers who are not steroid dependent. Takes several months to become effective. Usually started alongside slow steroid wean. Dose: 2.5 mg/kg (max 150 mg) on alternate days. Can crush tablets. Side-effects: leucopenia, gastro-intestinal effects and vasculitis. Monitor FBC and cunsel parents to seek medical attention if unusual or severe infection. Usually continued for at least 1-2 years.

Cyclophosphamide Significantly reduces risk of relapse in FRNS. Dose 2-3mg/kg orally once daily for 8 weeks. Alternate day dosing with tablets. Liquid special. Generally well tolerated: Weekly FBC during treatment. May lead to hair thinning Minimal effect on fertility. Preferred second-line agent in pre-pubertal children where there is steroid dependence. In peri- and post-pubertal children consider tacrolimus instead due to a theoretical increased risk of gonadal toxicity at this age. IV alternative to oral if concern about concordance 500 mg/m 2 monthly for 6 months.

Tacrolimus Effective at reducing frequency of relapses. Usually 3 rd line agent. Starting dose 0.15 mg (max 5mg) twice daily. Target trough level 4-8 nanograms/ml. Prescribe/dispense by brand: Prograf, Adoport, Modigraf, Adoport. If relapse free after 2 years on tacrolimus, it should be stopped. If early relapse, restart after induction of remission with prednisolone. If taking for >2 years, renal biopsy needed. If significant nephrotoxicity, switched to rituximab or mycophenolate. Dose related side-effects: headache, tremor, abdo pain, visual disturbance and hyperglycaemia.

Rituximab Indications: Frequent relapses on tacrolimus SRNS unresponsive to 3 months of tacrolimus FRNS/SDNS if poor concordance tacrolimus or levamisole Life-threatening nephrotic complications In FRNS/SDNS, usually consolidates remission for at least 6 months Dose: 375 mg/m 2 : Increasing rate, pre-med. Hepatitis B status must be determined before starting. Repeat dose on relapse / B-cell repopulation. Long-term effects not known. On current evidence, give maximum 4 prophyactic doses before waiting to see if in long-term remission.

Mycophenolate Effective as add-on agent when already on tacrolimus: Some evidence as a sole prophylactic agent less effective than ciclosporin or tacrolimus. If used with tacrolimus, dose is 300 mg/m 2 bd but due to GI side effects often started at lower dose initially. Dose if used without tacrolimus is 600 mg/m 2 bd, but again start at low dose. Prescribe by brand.

Steroid Resistant NS If unresponsive after 4 weeks of prednisolone give methylprednisolone (300 mg/m 2 ) for 3 days. If no response renal biopsy indicated. Tacrolimus then usually commenced. Followed if needed by rituximab. Focal and segmental sclerosis (FSGS) More steroid-resistant disease with a poorer prognosis Other drugs to consider for persistent nephrotic states: ACE inhibitors and ARBs; statins; and anticoagulants or antiplatelets.

Any questions?

NUH Pharmacy